205 related articles for article (PubMed ID: 12888371)
1. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease.
Duffy SW; Tabar L; Vitak B; Day NE; Smith RA; Chen HH; Yen MF
Eur J Cancer; 2003 Aug; 39(12):1755-60. PubMed ID: 12888371
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening.
Yen MF; Tabár L; Vitak B; Smith RA; Chen HH; Duffy SW
Eur J Cancer; 2003 Aug; 39(12):1746-54. PubMed ID: 12888370
[TBL] [Abstract][Full Text] [Related]
3. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program.
Ernster VL; Barclay J; Kerlikowske K; Wilkie H; Ballard-Barbash R
Arch Intern Med; 2000 Apr; 160(7):953-8. PubMed ID: 10761960
[TBL] [Abstract][Full Text] [Related]
4. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.
Duffy SW; Dibden A; Michalopoulos D; Offman J; Parmar D; Jenkins J; Collins B; Robson T; Scorfield S; Green K; Hall C; Liao XH; Ryan M; Johnson F; Stevens G; Kearins O; Sellars S; Patnick J
Lancet Oncol; 2016 Jan; 17(1):109-14. PubMed ID: 26655422
[TBL] [Abstract][Full Text] [Related]
5. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women.
Hendrick RE
Radiology; 2018 May; 287(2):391-397. PubMed ID: 29267146
[TBL] [Abstract][Full Text] [Related]
6. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
7. Benefit-to-harm ratio of the Danish breast cancer screening programme.
Beau AB; Lynge E; Njor SH; Vejborg I; Lophaven SN
Int J Cancer; 2017 Aug; 141(3):512-518. PubMed ID: 28470685
[TBL] [Abstract][Full Text] [Related]
8. Incidence of and treatment for ductal carcinoma in situ of the breast.
Ernster VL; Barclay J; Kerlikowske K; Grady D; Henderson C
JAMA; 1996 Mar; 275(12):913-8. PubMed ID: 8598618
[TBL] [Abstract][Full Text] [Related]
9. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project.
Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC
Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial.
Tabar L; Fagerberg G; Chen HH; Duffy SW; Smart CR; Gad A; Smith RA
Cancer; 1995 May; 75(10):2507-17. PubMed ID: 7736395
[TBL] [Abstract][Full Text] [Related]
11. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast.
Romero L; Klein L; Ye W; Holmes D; Soni R; Silberman H; Lagios MD; Silverstein MJ
Am J Surg; 2004 Oct; 188(4):371-6. PubMed ID: 15474428
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer.
Kerlikowske K; Barclay J; Grady D; Sickles EA; Ernster V
J Natl Cancer Inst; 1997 Jan; 89(1):76-82. PubMed ID: 8978410
[TBL] [Abstract][Full Text] [Related]
13. Update of the Swedish Two-County Trial of breast cancer screening: histologic grade-specific and age-specific results.
Tabar L; Vitak B; Chen HH; Prevost TC; Duffy SW
Swiss Surg; 1999; 5(5):199-204. PubMed ID: 10546517
[TBL] [Abstract][Full Text] [Related]
14. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
Ringberg A; Andersson I; Aspegren K; Linell F
Eur J Surg Oncol; 1991 Oct; 17(5):466-76. PubMed ID: 1657650
[TBL] [Abstract][Full Text] [Related]
15. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in cancers detected in patients older and younger than 50 years of age.
Evans WP; Starr AL; Bennos ES
Radiology; 1997 Aug; 204(2):489-91. PubMed ID: 9240541
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program.
Hofvind S; Lee CI; Elmore JG
Breast Cancer Res Treat; 2012 Aug; 135(1):291-9. PubMed ID: 22833199
[TBL] [Abstract][Full Text] [Related]
18. The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours.
Evans AJ; Pinder SE; Snead DR; Wilson AR; Ellis IO; Elston CW
Br J Cancer; 1997; 75(4):542-4. PubMed ID: 9052407
[TBL] [Abstract][Full Text] [Related]
19. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation.
Duffy SW; Tabar L; Vitak B; Yen MF; Warwick J; Smith RA; Chen HH
Ann Oncol; 2003 Aug; 14(8):1196-8. PubMed ID: 12881376
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
Miligy IM; Toss MS; Shiino S; Oni G; Syed BM; Khout H; Tan QT; Green AR; Macmillan RD; Robertson JFR; Rakha EA
Br J Cancer; 2020 Nov; 123(10):1513-1520. PubMed ID: 32773767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
